<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01293357</url>
  </required_header>
  <id_info>
    <org_study_id>MCB 0901</org_study_id>
    <nct_id>NCT01293357</nct_id>
  </id_info>
  <brief_title>A Study Evaluating Skin Irritation, Phototoxicity and Safety After Administration of LEO 90105 on Intact Skin of Healthy Japanese Male Subjects</brief_title>
  <official_title>A Phase 1 Study Evaluating Skin Irritation, Phototoxicity and Safety After Administration of LEO 90105 on Intact Skin of Healthy Japanese Male Subjects A Single Centre, Randomised, Controlled, Investigator Blinded Study With Intra-individual Comparison of the Active Formulation and Its Components</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the trial is to investigate skin irritation, phototoxicity and safety of LEO
      90105 and its components by patchtest (48 hours closed patch test and photo patch test) in
      healthy Japanese male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Skin irritation</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Patches</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 90105</intervention_name>
    <description>Ointment</description>
    <arm_group_label>Patches</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Japanese male subjects,

          -  Aged 20 to 40 years inclusive.

          -  Subjects without signs of skin irritation (erythema,dryness, roughness or scaling) on
             test sites.

          -  Subjects willing to follow the study procedures and complete the study Subjects having
             understood and signed a written informed consent.

          -  Subjects without abnormal in physiological test and clinical test in screening, and
             also judged as possible to participant the study by investigators.

        Exclusion Criteria:

          -  Body mass Index (BMI ) (body weight (kg)/height(m)Â²) outside the range 18-25 kg/m2

          -  History of alcohol, chemical or drug abuse

          -  History of allergic reaction to drugs or history of skin reaction to the tape

          -  Any systemic or cutaneous disease that could in any way confound interpretation of the
             study results (e.g. atopic dermatitis, eczema, psoriasis)

          -  Known sensitivity to any component of any of the formulations being tested

          -  Known hepatic or renal disorders

          -  Use of systemic, locally injected or inhaled corticosteroids within 4 weeks of study
             start (Day 1)

          -  Use of systemic vitamin D analogues, vitamin D or calcium supplements within 4 weeks
             of study start(Day 1)

          -  Use of any drug (systemic or topical) within 2 weeks of study start (Day 1)

          -  Use of non-marketed/other investigational products one month prior to or 5 half lives
             (for those the half life is longer than one month) and during the trial is not
             permitted

          -  Any abnormality found at medical interview before administration of the test drug,
             which will affect the clinical study as judged by the investigator

          -  History of or active photo-induced or photoaggravated disease (abnormal response to
             the sun light)

          -  Exposure to excessive or chronic ultraviolet (UV)radiation (i.e., sunbathing, tanning
             salon use, phototherapy)within four weeks prior to inclusion (Day 1) or planned during
             the study period

          -  Scars, moles, sunburn, or other blemishes in the test area which would interfere with
             grading

          -  Subjects whose partner wishes to become pregnant but is unwilling to use birth control
             during the study

          -  Any condition which, in the opinion of the investigator, would place the subject at an
             unacceptable risk if he participated in the study

          -  Any disease which are contradictions for treatment of the investigation products or
             for which treatment with the investigation products needs to be carefully considered
             (Subjects with any of the following conditions present on the area(s) to be treated
             with study medication: viral (e.g., herpes or varicella) lesions of the skin, fungal
             or bacterial skin infections, parasitic infections, skin manifestations in relation to
             syphilis or tuberculosis, rosacea, acne vulgaris, atrophic skin, striae atrophicae,
             fragility of skin veins, ichthyosis, acne rosacea, ulcers or wounds).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masanari Shiramoto, MD., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hakata Clinica LTA Clinical Pharmacology Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hakata Clinic LTA Clinical Pharmacology Center</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.leo-pharma.com/Home/Research-and-Development/Clinical-trial-disclosure/Clinical-trial-summaries-and-reports.aspx</url>
    <description>Clinical Trials at LEO Pharma</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2011</study_first_submitted>
  <study_first_submitted_qc>February 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2011</study_first_posted>
  <last_update_submitted>March 25, 2015</last_update_submitted>
  <last_update_submitted_qc>March 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Phototoxic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

